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Abstract
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely 
ineffective in pre-clinical and clinical settings and was therefore abandoned1–3. However, recently 
developed single cell based antibody cloning methods have uncovered a new generation of far 
more potent broadly neutralizing antibodies (bNAbs) to HIV-14,5. These antibodies can prevent 
infection and suppress viremia in humanized mice (hu-mice) and nonhuman primates, but their 
potential for human HIV-1 immunotherapy has not been evaluated6–10. Here we report the results 
of a first-in-man dose escalation phase 1 clinical trial of 3BNC117, a potent human CD4 binding 
site antibody11, in uninfected and HIV-1-infected individuals. 3BNC117 infusion was well 
tolerated and demonstrated favorable pharmacokinetics. A single 30 mg/kg infusion of 3BNC117 
reduced the viral load (VL) in HIV-1-infected individuals by 0.8 – 2.5 log10 and viremia remained 
significantly reduced for 28 days. Emergence of resistant viral strains was variable, with some 
individuals remaining sensitive to 3BNC117 for a period of 28 days. We conclude that as a single 
agent 3BNC117 is safe and effective in reducing HIV-1 viremia, and that immunotherapy should 
be explored as a new modality for HIV-1 prevention, therapy, and cure.
A fraction of HIV-1-infected individuals develop potent neutralizing serologic activity 
against diverse viral isolates4,5. Single cell cloning methods to isolate antibodies from these 
individuals12 revealed that broad and potent neutralization can be achieved by antibodies 
targeting many sites on the viral envelope5,13,14. Many of these antibodies can prevent 
infection, and some can suppress active infection in hu-mice or macaques6–10. Therefore, it 
is generally accepted that a vaccine eliciting such antibodies is likely to be protective against 
HIV-1. However, potent anti-HIV-1 bNAbs are highly somatically mutated and many carry 
other uncommon features such as insertions, deletions, or long complementary determining 
regions4,5,11,12,15, which may account for the difficulty in eliciting such antibodies by 
immunization. In view of the efficacy of passive bNAb administration in hu-mice and 
macaques7–9,16, it has been suggested that bNAbs should be administered passively, or by 
viral vectors for prevention and immunotherapy4,9,16. However, their safety and efficacy has 
not been tested in humans.
To determine whether the new generation of more potent bNAbs are safe and active against 
HIV-1 in humans, we initiated an open label phase 1 study (Fig. 1a) with 3BNC117, an anti-
CD4 binding site antibody cloned from a viremic controller11. 3BNC117 neutralizes 195 of 
237 HIV-1 strains comprising 6 different clades with an average IC50 of 0.08 μg/ml 
(Extended Data Fig. 1)11. 12 uninfected and 17 HIV-1-infected individuals (Table 1) were 
administered a single intravenous dose of 1, 3, 10 or 30 mg/kg of 3BNC117 (Extended Data 
Table 1a). 3BNC117 serum concentrations, plasma HIV-1 viral loads (VL), CD4+ and CD8+ 
T-cell counts, and safety were monitored closely (Fig. 1a, Extended Fig. 2, 3, and Extended 
Data Table 1b, 2). The two groups were comparable for gender, race and age (Table 1).
3BNC117 was generally safe and well tolerated at all doses tested in both uninfected and 
HIV-1-infected individuals. No grade 3, 4 or serious adverse events and no treatment-related 
laboratory changes were observed during 56 days of follow up (Extended Data Table 1b). 
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CD4+ or CD8+ T cell counts did not change after 3BNC117 infusion in the HIV-1-infected 
group possibly because initial CD4+ T cell counts were near normal in most participants 
(mean absolute CD4+ T cell count was 655 cells/μl, Extended Data Fig. 2).
Two different assays were used to measure 3BNC117 levels in serum: TZM.bl neutralization 
assay to measure activity, and anti-idiotype specific ELISA to measure antibody protein 
levels (Fig. 1b, Extended Data Fig. 3 and Extended Table 4, 5). With few exceptions the two 
assays were generally in agreement in both groups (Fig. 1b and Extended Data Fig. 3). 
However, elimination of 3BNC117 activity was more rapid in the HIV-1-infected group 
resulting in an estimated t1/2 of average around 9 days as opposed to around 17 days in 
uninfected individuals (Fig. 1b and Extended Data Table 4, 5). We conclude that 3BNC117 
has pharmacokinetic properties consistent with a typical human IgG1 in uninfected 
individuals and a somewhat faster decay rate in HIV-1-viremic individuals. Similar antigen 
dependent enhanced clearance has been reported with anti-cancer antibodies17. Although 
there may be other explanations, we speculate that the increased rate of antibody elimination 
in the presence of HIV-1 is due to accelerated clearance of antigen-antibody complexes.
Viral loads were measured by standard assays or by single copy assays. Baseline VLs in 
HIV-1-infected individuals not on ART varied from 640 – 53,470 copies/ml (mean 9,420 
copies/ml). Two participants were on ART at the time of antibody infusion but had 
detectable baseline VLs (30 and 100 copies/ml). (Table 1, Extended Data Table 2a).
Virologic responses correlated with antibody dose. Infected individuals receiving 1 or 3 
mg/kg 3BNC117 doses showed only small and transient changes in viremia consisting of 
increases of up to 3-fold one day after infusion, followed by a short temporary decrease, and 
rapid return to baseline (Fig. 2, Extended Data Fig. 4, and Extended Data Table 2a). The 
magnitude and kinetics of the initial increase in viremia were consistent with those seen with 
viral entry inhibitors18.
In contrast, 10 out of 11 individuals receiving 10 or 30 mg/kg infusions responded by 
dropping their VLs by up to 2.5 log10 (Fig. 2, Extended Data Fig. 4 and Extended Data 
Table 2a). 2 individuals off ART received the 10 mg/kg dose, of whom 1 responded with 
1.36 log10 decline in viremia and the other did not (Fig. 2 and Extended Data Table 2a). The 
individual that did not respond was infected with a virus that was completely resistant to 
3BNC117 (2C4; IC50 > 20 μg/ml; Fig. 3 and Extended Data Table 3). All 8 individuals that 
received the 30 mg/kg dose of 3BNC117 showed highly significant and rapid decreases in 
their viral loads that varied between −0.8 to −2.5 log10 (Fig. 2 and 3 and Extended Data 
Table 2a, b). The magnitude of the decline was related to the starting VL and the sensitivity 
of the subjects’ autologous virus to 3BNC117 (Fig. 2 and 3, Extended Data Fig. 5). The 
median time to reach the nadir in viremia was 7 days, and the mean drop in VL was 1.48 
log10 at nadir. When compared to all available pre-treatment measurements, the drop in 
viremia was highly significant from days 4 through 28 (Fig. 2 and Extended Data Table 2b). 
Although the limited data set does not allow us to determine viral set point, 4 of the 8 
individuals receiving a single 30 mg/kg infusion did not entirely return to day 0 pre-infusion 
levels during the observation period of 56 days (Fig. 2 and 3, Extended Data Table 2a).
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To further examine the virologic effects of 3BNC117 immunotherapy, autologous viral 
isolates were obtained from cultured PBMCs before (day 0) and after (day 28) antibody 
infusion. Paired samples from 12 of the 17 HIV-1-infected individuals were tested for 
3BNC117-sensitivity (Fig. 3 and Extended Data Table 3). Samples obtained from 
individuals infused with 1 mg/kg showed 35- and 13.5-fold decreases in 3BNC117-
sensitivity indicating that the antibody exerts selective pressure on HIV-1 even at the lowest 
dose (2A3, 2A4; Fig. 3). Similar changes in sensitivity were seen for some (2B1, 2C5) 
individuals treated with 3 and 10 mg/kg, but others remained 3BNC117-sensitive throughout 
(2B3) (Fig. 3, Extended Data Table 3). Similarly, at 30 mg/kg only 2 out of 5 individuals 
tested showed greater than 5-fold reduction in 3BNC117-sensitivity on day 28 (Extended 
Data Table 3). In contrast, 2C1, 2D1, 2D3 showed only 3.2-, 1.3- and 2.7 fold changes in 
sensitivity and these individuals did not rebound to baseline viremia levels at day 28 (Fig. 2 
and 3). We conclude that in some individuals HIV-1 develops high-level resistance to 
3BNC117 by 28 days after a single dose, while in others it does not.
To examine the molecular nature of the changes in HIV-1 in response to 3BNC117, we 
cloned and sequenced HIV-1 envelopes from paired plasma samples from 10 individuals 
before and 28 days after infusion. Evidence for antibody-induced selection was seen in some 
but not all samples analyzed (Fig. 4, Supplementary Fig. 1). For example, 2C5, who received 
a 10 mg/kg infusion, selected for a G459D mutation in 15 out of 23 env sequences, while the 
remainder showed a longer V5 loop. The G459D mutation alters the CD4bs and can result in 
resistance to 3BNC1179. Changes in the V5 loop can alter sensitivity to anti-CD4bs 
antibodies by steric clashing with the heavy or light chains of 3BNC117-type antibodies. 
Similarly, 10 or 30 mg/kg infusions selected single mutations at Q363H (2E1), S461D 
(2E2), and S274Y (2E2) (Fig. 4, Supplementary Fig. 1). These changes may alter sensitivity 
to 3BNC117 by interfering with binding5. Selection in these 3 individuals is also indicated 
by the emergence of a distinct group of closely related sequences in phylogenetic trees (Fig. 
4, Supplementary Fig. 1). Consistent with the molecular analysis, and the viral culture data 
(Fig. 3), pseudoviruses produced from serum of 2C5 from days 0 and 28 showed high level 
3BNC117-resistance, whereas the changes in pseudoviruses produced from 2C1, 2D1, 2E1 
and 2E2 were modest (Fig. 4 and Extended Data Table 3). In contrast, autologous viral 
isolates from individuals, who did not become resistant, or had only small changes in 
sensitivity, such as 2B3, showed little if any evidence of selection. We conclude that a single 
infusion of 3BNC117 leads to selection for high-level resistance in some but not all 
individuals.
Although immunotherapy was initially used to treat infectious diseases, the great majority of 
therapeutic monoclonal antibodies are currently used to treat cancer and autoimmune 
diseases. This form of therapy has been shown to be highly effective, well tolerated, and to 
function in large part by engaging the host immune system through Fc receptors19.
In contrast, a role for antibodies in controlling HIV-1 infection has been difficult to establish. 
For example, the overall course of infection is not thought to be altered in individuals that 
develop bNAbs20. Moreover, first generation anti-HIV-1 bNAbs with limited breadth and 
activity produced little if any measurable effects in hu-mice or viremic individuals3,21. 
However, antibodies can put strong selective pressure on the virus in individuals that develop 
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anti-HIV-1 antibody responses22–24. In addition, recent studies in hu-mice showed that, 
when administered as monotherapy, new generation bNAbs can transiently reduce VLs, and 
in combination they control viremia for as long as concentrations remain in the therapeutic 
range6,9. In contrast, single antibodies led to control of viremia in SHIV-infected macaques 
for as long as antibody levels remained therapeutic, and immune escape was rarely 
observed7,8. The surprising difference between hu-mice and macaques might be attributed in 
part to an intact host immune system in the macaque, including endogenous antibodies25, or 
differences between SHIV and HIV-1 infection. Our data establish that passive infusion of 
single bNAbs can have profound effects on HIV-1 viremia in humans.
Combinations of antiretroviral drugs are the standard of care for HIV-1 infection because 
resistance develops to single agents26. Similarly, monotherapy with 3BNC117 alone is 
insufficient to control infection, and we expect that antibody-drug or antibody-antibody 
combinations will be required for complete viremic control. Although the current generation 
of drugs is less expensive than antibodies, the latter have very long half-lives and have the 
potential to kill infected cells and to enhance host immunity by engaging Fc receptors19,27. 
Moreover, anti-HIV-1 antibodies can be made 100-fold more potent by molecular 
engineering28. Finally, the combination of antibodies with agents that activate latent viruses 
can interfere with the HIV-1 reservoir in hu-mice29 and may be critical to HIV-1 eradication 
strategies.
Given the difficulties in developing an HIV-1 vaccine and in eradicating established 
infection, passive transfer of monoclonal antibodies is being considered for HIV-1 
prevention, therapy, and cure. Our data establish the principle that monoclonal antibodies 
can be both safe and effective against HIV-1 in humans. Antibody-mediated immunotherapy 
differs from currently available drugs in that it has the potential to impact the course of 
HIV-1 infection by directly engaging host immunity.
Methods
Study design
An open-label, dose-escalation phase 1 study was conducted in uninfected (Group 1) and 
HIV-1-infected subjects (Group 2; www.clinicaltrials.gov; NCT02018510). Study 
participants were enrolled sequentially according to eligibility criteria. A standard “3+3” 
phase I trial design was be used in the dose-escalation phase of the study. 3BNC117 was 
administered as a single intravenous infusion at four dose levels: 1mg/kg (subjects 1A1, 
1A2, 1A3, 2A1, 2A3, 2A4), 3 mg/kg (subjects 1B1, 1B2, 1B3, 2B1, 2B2, 2B3), 10 mg/kg 
(subjects 1C1, 1C3, 1C4, 2C2, 2C4, 2C5) or 30 mg/kg (subjects 1E2, 1E3, 1E5, 2D1, 2C1, 
2D3, 2E1, 2E2, 2E3, 2E4, 2E5), at a rate of 100 or 250 ml/hr. Study participants were 
followed for 56 days after infusion. All participants provided written informed consent 
before participation in the study and the study was conducted in accordance with Good 
Clinical Practice. The protocol was approved by the Federal Drug Administration in the 
USA, the Paul Ehrlich Institute in Germany and the Institutional Review Boards at the 
Rockefeller University and the University of Cologne.
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Study Participants
All study participants were recruited at the Rockefeller University Hospital, New York, USA 
and at the University Hospital Cologne, Cologne, Germany. Eligible subjects were adults 
aged 18 – 65 years, HIV-1-infected or uninfected, and without concomitant hepatitis B or C 
infections. HIV-1-infected subjects enrolled in study groups 2A through 2E were ART-
experienced or naïve. In groups 2A through 2D, subjects were either off standard ART for at 
least 8 weeks prior to study participation and had plasma HIV-1 RNA levels between 2,000 
and 100,000 copies/ml, or they were on standard ART but had plasma HIV-1 RNA levels > 
20 copies/ml, measured on two separate occasions at least 1 week apart. Subjects recruited 
into group 2E were HIV-1-infected, off ART (2,000 – 100,000 copies/ml), and differed from 
the other groups in that they were pre-screened for sensitivity to 3BNC117 as described 
below. Subjects with CD4+ T-cell counts < 300 cells/μl, clinically relevant deviations from 
normal physical findings, abnormal electrocardiogram (ECG), and/or laboratory 
examinations were excluded. Women of childbearing potential were required to have a 
negative result of a serum pregnancy test on the day of 3BNC117 infusion. HIV-1-infected 
individuals, who were not on standard ART at enrollment, were given the option to initiate 
ART 6 weeks after 3BNC117 infusion.
Study Procedures
The appropriate volume of 3BNC117 was calculated according to study dose group, diluted 
in sterile normal saline to a total volume of 100 or 250 ml, and administered intravenously 
over 60 minutes. Study participants received 3BNC117 on day 0 and remained under close 
monitoring in the inpatient unit of the Rockefeller University Hospital for 24 hours. 
Participants returned for frequent follow up visits for safety assessments that included 
physical examination, measurement of clinical laboratory parameters such as hematology, 
chemistries, urinalysis, coagulation times, pregnancy tests (for women) as well as HIV-1 
viral loads and CD4+ and CD8+ T cell counts (Fig. 1a). Adverse events were graded 
according to the DAIDS AE Grading Table (HIV-1-infected groups) or the Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials (uninfected groups). Blood samples (30 to 120 ml) were collected before and at 
multiple times after 3BNC117 infusion. Samples were processed within 4h of collection, 
and serum and plasma samples were stored at −80°C. PBMCs were isolated by density 
gradient centrifugation. The absolute number of peripheral blood mononuclear cells was 
determined by an automated cell counter (Vi-Cell XR; Beckman Coulter), and cells were 
cryopreserved in fetal bovine serum plus 10% DMSO.
Plasma HIV-1 RNA Levels
Plasma was collected for measuring HIV-1 RNA levels at screening (from day −49 to day 
−14), the day −7 pre infusion visit (from day −42 to day −2), day 0 (before infusion), and on 
days 1, 4, 7, 14, 21, 28, 42 and 56. HIV-1 RNA levels were determined using the Roche 
COBAS AmpliPrep/COBAS TaqMan HIV-1 Assay, Version 2.0, which detects 20–10×106 
copies/ml, or by the ABBOTT RealTime Assay, which detects 40–10×106 copies/ml. In 
samples with HIV-1 RNA < 20 copies/ml, viremia was measured by a quantitative real-time, 
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reverse transcriptase (RT)-initiated PCR (RT-PCR) assay that can quantify HIV-1 RNA 
down to 1 copy/ml as previously described31.
CD4+ and CD8+ T cells
CD4+ and CD8+ T-cell counts were determined at screening, on day 0 (before infusion), and 
day 28 by a clinical flow cytometry assay, performed at LabCorp or at the University 
Hospital Cologne. Cells were analyzed by flow cytometry. Leukocytes were determined as 
CD45+ cells. Percentage of cells positively stained for CD3, CD4, CD8 as well as the 
CD4/CD8 ratio were analyzed with the BD Multiset software (BD Biosciences).
3BNC117 Study Drug
3BNC117 is a recombinant, fully human IgG1κ mAb recognizing the CD4 binding site on 
the HIV-1 envelope11. The antibody was cloned from an HIV-1-infected viremic controller 
in the International HIV Controller Study11,32, expressed in Chinese hamster ovary cells 
(clone 5D5-5C10), and purified using standard methods. The 3BNC117 drug substance was 
produced at Celldex Therapeutics Fall River (MA) GMP facility, and the drug product was 
fill-finished at Gallus BioPharmaceuticals (NJ). The resulting purified 3BNC117 was 
supplied as a single use sterile 20 mg/ml solution for intravenous injection in 8.06 mM 
sodium phosphate, 1.47 mM potassium phosphate, 136.9 mM sodium chloride, 2.68 mM 
potassium chloride, and 0.01% polysorbate 80. 3BNC117 vials were shipped and stored at 
4°C.
Measurement of 3BNC117 serum levels
Serum levels of 3BNC117 were determined by using two separate methods (ELISA and 
TZM.bl). 3BNC117 serum concentrations were measured by a validated sandwich ELISA. 
Plates (Sigma-Aldrich PN: CLS3590 96-well, High Bind, polystyrene) were coated with 4 
μg/ml of an anti-idiotypic antibody specifically recognizing 3BNC117 (anti-ID 1F1 mAb), 
and incubated overnight at 2–8°C. After washing, plates were blocked for 1 h with 5% BSA. 
Serum samples, QCs and standards were added (1:50 minimum dilution in 5 % BSA) and 
incubated for 1 h at room temperature. 3BNC117 was detected using an HRP-conjugated 
mouse anti-human IgG kappa chain specific antibody (Abcam PN: ab79115) and the HRP 
substrate tetra-methylbenzidine. 3BNC117 concentrations were then interpolated from a 
standard curve of 3BNC117 using a 4 parameter logistic curve-fitting algorithm. The 
reference standard and positive controls were created from the drug product lot of 3BNC117 
utilized in the clinical study. The capture anti-idiotypic antibody was produced by 
immunizing BALB/c mice with a Fab’ fragment of 3BNC117 and plasma was tested for the 
presence of neutralizing antibodies in an ELISA. Briefly, the HIV-1 antigen (2CC core 
protein) was coated to a plate and blocked. Plasma dilutions were pre-incubated with a sub-
saturating concentration of 3BNC117 then added to the plate. Binding to the antigen was 
detected with an HRP-conjugated goat anti-mouse IgG-Fc specific antibody. Plasma was 
considered neutralizing if it was able to block the binding of 3BNC117 to the antigen coated 
plate. Two mice were selected for fusion. Those hybridomas that showed high specificity 
when comparing binding to 3BNC117 versus binding to the irrelevant human IgG1 antibody 
were selected to expand, screened in the neutralization assay as described above, subcloned 
and purified for use in the anti-idiotype specific ELISA.
Caskey et al. Page 7
Nature. Author manuscript; available in PMC 2016 June 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In addition, the concentration of active 3BNC117 was determined by TZM.bl neutralization 
assay7,8. Serum samples were heat-inactivated for 1h at 56°C and measured for neutralizing 
activity against an HIV-1 strain that was highly sensitive to 3BNC117 but resistant to any 
autologous HIV-1 neutralizing serum activity. In all uninfected subjects serum samples were 
tested against Q769.d22 and ID50 values were derived by using a 5-parameter curve fitting, 
considering accurate within the pre-established limits (3-fold variation with a 20% error 
rate). The serum concentration of active 3BNC117 was calculated by taking into account the 
sera ID50 titers multiplied by the known IC50 of 3BNC117 for Q769.d22. In HIV-1-infected 
subjects pre-infusion samples were first tested against a panel of 3BNC117-sensitive HIV-1 
strains that included Q769.d22 (Clade A1, Tier 2), YU2.DG (Clade B, Tier 2), Q259.d2.17 
(Clade C, Tier 1B), Q842.d12 (Clade A1, Tier 2), ZM135M.PL10a (Clade C, Tier 2), and 
TRO.11 (Clade B, Tier 2). A single strain per subject was selected that showed no or only 
minimal background activity and 3BNC117 serum levels were determined in the same way 
as described for Q769.d22.
Pharmacokinetic analysis
Blood samples were collected immediately before, at the end, 0.5, 3, 6, 9, 12 and 24 hours 
after completion of the 3BNC117 infusion, and on days 2, 4, 7, 14, 21, 28, 42 and 56. 
3BNC117 serum levels were obtained from ELISA (Celldex Therapeutics) and TZM.bl 
neutralization assay, and PK-parameters were estimated by performing a non-compartmental 
analysis (NCA) using WinNonlin 6.3.
Neutralization assay
Serum samples, viral supernatants, and control antibodies were tested against HIV-1 
envelope pseudoviruses as previously described33,34.
Virus cultures
Autologous virus was retrieved from HIV-1 infected individuals as previously described35. 
Briefly, healthy donor PBMCs were obtained by leukapheresis from a single donor. Cells 
were cultured at a concentration of 5 × 106/ml in Iscove’s Modified Dulbecco’s Medium 
(IMDM; Gibco) supplemented with 10% fetal bovine serum (FBS; HyClone, Thermo 
Scientific), 1% Penicillin/Streptomycin (Gibco), and 1 μg/ml Phytohemagglutinin (Life 
Technologies) at 37°C and 5% CO2. After 2–3 days, 5×106 cells were transferred into 
IMDM supplemented with 10% FBS, 1% Penicillin/Streptomycin, 5 μg/ml polybrene 
(Sigma), and 10 U/ml of IL-2, and co-incubated with 2–3 × 106 PBMCs from the study 
participants obtained before and 28 days or later after 3BNC117 infusion (Extended Data 
Table 3). Media was replaced on a weekly basis and culture supernatants quantified using 
the Alliance HIV-1 p24 Antigen ELISA kit (PerkinElmer) according to the manufacturer’s 
instructions. TCID50s were determined for all HIV-1 containing supernatants
33
,
34
 and then 
tested for sensitivity against 3BNC117 in a TZM.bl neutralization assay. Outgrowth of 
autologous virus isolates from subjects with low level viremia was performed as previously 
described36. Briefly, 2–5 million CD4+ T cells were cultured in the presence of 10 million 
irradiated healthy donor PBMCs and 3 million healthy donor PHA stimulated CD8+ 
depleted lymphoblasts. Lymphoblasts were replenished weekly by adding 3 million healthy 
donor PHA stimulated CD8+ depleted lymphoblasts. Blood samples and leukopheresis were 
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collected under separate IRB-approved protocols and after study participants provided 
informed consent.
Sequence analysis
HIV-1 RNA was extracted from plasma samples using the Qiagen MinElute Virus Spin kit 
(Qiagen) followed by first strand cDNA synthesis using SuperScript III reverse transcriptase 
(Invitrogen Life Technologies) and the antisense primer env3out 5′–
TTGCTACTTGTGATTGCTCCATGT–3′37 or 5′–
GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG–3′6. gp160 env was amplified 
using envB5out 5′–TAGAGCCCTGGAAGCATCCAGGAAG–3′ and envB3out 5′–
TTGCTACTTGTGATTGCTCCATGT–3′ in the first round and second round nested primers 
envB5in 5′–CACCTTAGGCATCTCCTATGGCAGGAAGAAG–3′ and envB3in 5′–
GTCTCGAGATACTGCTCCCACCC-3′. First round PCR was performed using a High 
Fidelity Platinum Taq (Invitrogen) at 94°C, 2 min; (94°C, 15 sec; 55°C 30 sec; 68°C, 4 min) 
× 35; 68°C, 15 min. Second round PCR was performed with 2 μl of 1. PCR product as 
template and Phusion Hot Start Polymerase at 98°C, 30 sec; (98°C, 8 sec; 55°C, 20 sec; 
72°C, 1 min) × 35; 72°C, 6 min. gp120 env was amplified using first round primers and 
conditions as described, but second round was performed by using second round nested 
primers 5′–TAGAAAGAGCAGAAGACAGTGGCAATGA-3′ and 5-
′TCATCAATGGTGGTGATGATGATGTTTTTCTCTCTGCACCACTCTTCT-3′. Second 
round PCR was performed with 1 μl of 1. PCR product as template and High Fidelity 
Platinum Taq (Invitrogen) at cycling conditions, 94°C, 2 min; (94°C, 15 sec; 58°C, 35 sec; 
68°C, 2 min and 30 sec) × 35; 68°C, 10 min. Following the second-round PCR 
amplification, 0.5 μl Taq polymerase was added to each 50 μl reaction and an additional 
72°C extension for 15 min was performed to add 3′dA overhangs for cloning inserts into 
pCR4-TOPO. PCR amplicons were gel purified and ligated into pCR4-TOPO (Invitrogen) or 
pcDNA3.1 (Invitrogen), followed by transfection into MAX Efficiency Stbl2 Competent 
Cells (Life Technologies). Individual colonies were analyzed for insert length by PCR, and 
successfully cloned envelopes sequenced by a set of env specific primers. Sequence 
alignments and mutation analysis of gp120 and gp160 was performed by using Geneious Pro 
software, version 5.6.7 (Biomatters Ltd.), and residues were numbered according to HXBc2. 
Phylogenetic trees were generated using the PhyML tool at the Los Alamos HIV website38, 
and sequence analysis was performed using Antibody database by Anthony West39. 
Logograms were generated using the Weblogo 3.0 tool40. Selected sequences were used to 
generate pseudovirues and tested for 3BNC117 sensitivity in a TZM.bl assay37.
Statistical analyses
The sample size to detect > 1 log10 decline in viremia with 80% power at 5% of 
significance was determined to be 5 HIV-1-infected individuals, not on ART, infected with 
3BNC117-sensitive viruses assuming that the standard deviation would be similar to 
3BNC117 effects in hu-mice (Horwitz et al. 2013). Adverse events were summarized by the 
number of subjects who experienced the event, by severity grade and by relationship to 
3BNC117 according to the DAIDS AE Grading Table (HIV-1-infected groups) or the 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials (uninfected groups). PK-parameters were estimated by performing a 
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non-compartmental analysis (NCA) using WinNonlin 6.3. CD4+ and CD8+ T cell counts 
before and after 3BNC117 were analyzed by one-way ANOVA. To assess the changes in 
HIV-1 viral loads, we used a mixed-effect linear model where dose and time were fixed 
effects and random intercepts for each participant. These models take full advantage of the 
repeated measure structure of the data while estimating parameters for each dose 
simultaneously, hence improving the power of small study groups. The final model was 
fitted assuming an AR(1) correlation structure over time, which was the best in terms of 
AIC/BIC criteria. The significance of the effect of 3BNC117 on viral load, defined as 
change between each time point and day 0, was assessed using least-squares means within 
each dose group (Extended Data Table 2b). Sensitivity analysis was also carried out with 
variations of these models and the same conclusions were achieved. Pearson and 
nonparametric Spearman coefficients were calculated to assess the correlation between 
maximum drop in viremia after 3BNC117 infusion and baseline HIV-1 viral load or baseline 
sensitivity of autologous viruses to 3BNC117.
Extended Data
Extended Data Figure 1. 
HIV-1 neutralizing activity of 3BNC117. a. Summary of 3BNC117 neutralizing in vitro 
activity based on 237 HIV-1 isolates comprising 6 different clades. Data were retrieved from 
the ‘AntibodyDatabase’ by Anthony West (West et al., PNAS, 2013). b. Illustration of the 
fraction (i.e. % coverage; y-axis) of HIV-1 isolates that are neutralized at a given IC50 
(μg/ml; x-axis) using the same data set.
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Extended Data Figure 2. 
CD4+ and CD8+ T cell counts before and after 3BNC117 infusion. a. Absolute numbers 
(cells/μl) of CD4+ and CD8+ T cell counts of all enrolled HIV-1-infected participants at 
screen, on the day of 3BNC117 infusion (day 0), and at day 28 after infusion. b. Percentage 
of CD4+ and CD8+ T cells for the same subjects and time points. Mean and standard 
deviation are indicated in red and black, respectively. No significant differences between 
pre-infusion and post infusion levels were detected by using One-way ANOVA.
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Extended Data Figure 3. 
3BNC117 serum concentration and activity in single subjects. Serum levels of 3BNC117 in 
all uninfected (a) and HIV-1-infected (b) individuals that received 1, 3, 10, or 30 mg/kg 
3BNC117 at day 0. Antibody levels were measured by a sandwich ELISA using an 
anti-3BNC117 specific antibody (green) or by measuring the 3BNC117 serum activity in a 
TZM.bl neutralization assay (blue).
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Extended Data Figure 4. 
3BNC117 sensitivity and changes in viremia in 2 ART-treated subjects 3BNC117 sensitivity 
and changes in viremia of subjects 2B2 and 2C2. Both subjects were on ART when enrolled 
in the study and received a single dose (2B2, 3 mg/kg; 2C2, 10 mg/kg) of 3BNC117 at day 
0. The left y-axis shows log10 change in viremia from baseline, and right y-axis shows 
antibody level measured in ELISA. Blue line reflects change in VL and dotted gray line 
antibody level. Numbers indicate IC50s for 3BNC117 of autologous viral isolates measured 
by TZM.bl assay, color-coded as indicated on the right.
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Extended Data Figure 5. 
Correlating viral decay with 3BNC117 sensitivity and starting viral load. a. Maximum 
decline in viral load in ART-untreated HIV-1-infected participants with baseline 3BNC117-
sensitive viruses (IC50 < 1 μg/ml) versus pretreatment (day 0) viral load (Pearson coefficient 
r = 0.72 p = 0.03; Spearman coefficient rho = 0.78, p = 0.02). b. Maximum drop in viral load 
in HIV-1-infected and 3BNC117-sensitive individuals receiving a 10 or 30 mg/kg dose of 
3BNC117 (y-axis) versus baseline autologous virus sensitivity to 3BNC117 (x-axis; Pearson 
coefficient r = 0.69 p = 0.03; Spearman coefficient rho = 0.41, p = 0.23).
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Extended Data Table 1
Baseline characteristics of HIV-1-infected individuals and 3BNC117 safety data. a. Baseline 
characteristics of HIV-1-infected individuals. *, absolute CD4 T cell count was 309 and 302 
cells/mm at screening. **, DRV/r/TDF/FTC, darunavir, ritonavir tenofovir, emtricitabine; 
ATV/r/3TC/ZDV – atazanavir, ritonavir, lamividune, zidovudine. ND, Not Determined. b. 
3BNC117 safety data. AE, adverse events. Subject 2D3 developed herpes zoster involving a 
lumbar dermatome 35 days after infusion. The event was graded as moderate and considered 
not related to 3BNC117.
a
Study ID 3BNC117 dose Age
Years 
since 
HIV 
Diagnosis
Current ART regimen Clade HIV-RNA level (copies/ml)
abs. 
CD4* 
T cell 
count 
(day 
0; 
cells/
mm3)
2A1 1 mg/kg 35 11 ART naïve B 3,210 674
2A3 1 mg/kg 39 14 Off ART B 43,650 520
2A4 1 mg/kg 42 8 ART naïve B 5,340 607
2B1 3 mg/kg 20 1 Off ART ND 4,090 264*
2B2 3 mg/kg 48 20 DRV/r/TDF/FTC** ND 100 706
2B3 3 mg/kg 20 1 ART naïve B 38,190 777
2C2 10 mg/kg 51 12 ATV/r/3TC/ZDV** ND 30 728
2C4 10 mg/kg 54 23 Off ART ND 820 805
2C5 10 mg/kg 50 4 ART naïve B 9,260 245*
2D1 30 mg/kg 33 3 ART naïve B 53,470 980
2C1 30 mg/kg 51 17 Off ART B 47,650 1129
2D3 30 mg/kg 33 0.5 ART naïve ND 640 618
2E1 30 mg/kg 21 2 ART naïve B 15,780 847
2E2 30 mg/kg 46 1.5 ART naïve B 6,990 513
2E3 30 mg/kg 23 1.5 ART naïve BF 22,030 590
2E4 30 mg/kg 38 1 ART naïve ND 32,220 603
2E5 30 mg/kg 30 1 ART naïve ND 3,610 532
b
Adverse Events No. AEs %of reported AEs No. possibly related No. Mild No. Moderate No. Severe
Uninfected (No. of AEs) HIV-1-infected (No. of AEs)
1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg
Rhinorrhea and/or cough 10 16.9 3 8 2 0 1 1 0 1 1 0 0 6
Malaise 7 11.9 5 5 2 0 1 1 2 0 1 2 0 0
Headache 6 10.2 3 5 1 0 0 0 0 1 1 0 1 3
Diarrhea 5 8.5 1 2 1 0 1 1 0 0 1 0 1 1
Myalgia/arthralgia (localized) 4 6.8 1 3 1 0 0 0 0 0 1 0 3 0
Sore throat 4 6.8 2 4 0 0 1 1 0 0 0 1 1 0
Tenderness 3 5.1 1 3 0 0 0 0 0 1 1 0 1 0
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bAdverse Events No. AEs %of reported AEs No. possibly related No. Mild No. Moderate No. Severe
Uninfected (No. of AEs) HIV-1-infected (No. of AEs)
1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg 30 mg/kg
Increased Lacrimation 2 3.4 2 2 0 0 0 0 0 1 0 0 0 1
Myalgia 2 3.4 1 2 0 0 0 0 0 0 0 0 1 1
Chills 2 3.4 0 1 1 0 0 1 0 0 1 0 0 0
Conjunctival erythema 2 3.4 2 2 0 0 0 0 1 0 1 0 0 0
Fevershiness 2 3.4 0 1 1 0 0 0 0 0 1 1 0 0
Nausea 2 3.4 1 2 0 0 0 0 0 1 1 0 0 0
Pruritus 2 3.4 2 2 0 0 0 0 0 0 0 0 0 2
Blurry vision 1 1.7 1 1 0 0 0 0 0 0 0 0 1 0
Decreased appetite 1 1.7 0 1 0 0 0 0 0 0 1 0 0 0
Erythema 1 1.7 1 1 0 0 0 0 0 1 0 0 0 0
Paresthesia upper extremity 1 1.7 0 1 0 0 0 0 0 0 1 0 0 0
Shingles 1 1.7 0 0 1 0 0 0 0 0 0 0 0 1
Vomiting 1 1.7 1 1 0 0 0 0 0 0 1 0 0 0
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Extended Data Table 2
HIV-1 RNA levels and viral decay mixed-effect linear model. a. HIV-1 RNA levels. Subjects 
2B2 and 2C2 were on ART. Subject 2D3 started ART after day 42. Screen was performed 
between day −49 and day −14. Viremia measurements at “Pre” were performed between day 
−42 and day −2.
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Extended Data Table 3
Sensitivity of autologous virus isolates and cloned HIV-1 envelopes to 3BNC117. ND, Not 
Determined.
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Extended Data Table 4
Pharmakokinetics of 3BNC117 based on a 56-day period post infusion. Estimation of PK 
parameters retrieved from study participants (ID) up to 8 weeks post 3BNC117 infusion. 
3BNC117 was administered at 1, 3, 10, and 30 mg/kg in uninfected (Negative) and HIV-1-
infected (Positive) individuals. 3BNC117 serum concentrations were determined by ELISA 
or TZM.bl assay (see Methods). PK-parameters were obtained by performing a non-
compartmental analysis (NCA) using WinNonlin 6.3. T1/2 was estimated using values 
between Lambda upper/lower. n.d., PK parameters were not determined because of 
insufficient data or an extrapolated AUC_inf that exceeded 25%. Values in red indicate 
extrapolated AUC_inf >10%.*, Days post infusion of 3BNC117.
ID HIV-1/ART 3BNC117(mg/kg) Method
Cmax
(μg/ml)
adjusted
R-squared
Estimated
T1/2 (days)
Lambda
(lower)*
Lambda
(upper)*
AUC
(INF_pred) Tlast*
Clast
(μg/ml)
AUC_%
Extrap_pred
1A1 Negative 1
ELISA 27.4 n.d. n.d. – – n.d. – – n.d.
TZM.bl 27.4 0.936 21.32 14 42 184.0 42 1.2 19.2
1A2 Negative 1
ELISA 18.8 n.d. n.d. – – n.d. – – n.d.
TZM.bl 27.8 0.893 12.89 7 42 181.7 42 1.0 9.0
1A3 Negative 1
ELISA 11.2 n.d. n.d. – – n.d. – – n.d.
TZM.bl 23.5 0.976 10.38 4 28 138.0 28 1.3 14.0
2A1 Positive/Off 1 ELISA 15.7 n.d. n.d. – – n.d. – – n.d.
2A3 Positive/Off 1 ELISA 22.7 n.d. n.d. – – n.d. – – n.d.
2A4 Positive/Off 1
ELISA 33.8 n.d. n.d. – – n.d. – – n.d.
TZM.bl 15.6 n.d. n.d. – – n.d. – – n.d.
1B1 Negative 3
ELISA 89.9 0.985 19.64 7 56 685.2 56 3.1 12.1
TZM.bl 70.9 0.881 24.30 7 56 483.7 56 2.7 17.9
1B2 Negative 3
ELISA 90.1 0.878 12.91 7 42 523.5 42 2.2 8.8
TZM.bl 116.0 0.936 10.04 7 42 481.2 42 1.4 4.6
1B3 Negative 3
ELISA 243.4 0.954 21.54 14 56 1017.3 56 4.2 12.1
TZM.bl 74.5 0.954 21.70 7 56 706.6 56 3.9 15.6
2B1 Positive/Off 3
ELISA 90.8 0.942 9.60 4 21 219.4 21 2.8 19.2
TZM.bl 57.4 0.994 10.28 7 28 245.9 28 1.9 12.1
2B2 Positive/On 3 ELISA 97.6 0.928 8.74 7 21 200.7 21 2.5 16.5
2B3 Positive/Off 3
ELISA 60.0 0.981 9.08 4 21 251.2 21 3.5 17.0
TZM.bl 32.6 0.994 9.19 4 28 129.8 28 1.0 10.1
1C1 Negative 10
ELISA 347.8 0.942 16.33 7 56 1667.9 56 5.9 7.5
TZM.bl 281.8 0.964 15.79 7 56 1598.9 56 5.6 7.3
1C3 Negative 10
ELISA 308.9 0.860 29.01 7 56 2529.4 56 15.8 23.5
TZM.bl 244.7 0.700 26.59 14 56 2228.5 56 13.1 19.3
1C4 Negative 10
ELISA 180.6 0.835 10.73 7 42 859.1 42 4.0 5.5
TZM.bl 230.7 0.990 10.56 14 56 1022.0 56 1.4 2.2
2C2 Positive/On 10 ELISA 326.8 0.866 10.87 7 42 904.5 42 2.7 5.6
2C4 Positive/Off 10
ELISA 178.2 0.944 6.92 4 28 550.2 28 2.8 5.1
TZM.bl 193.0 0.979 6.14 4 28 417.9 28 1.8 3.4
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ID HIV-1/ART 3BNC117(mg/kg) Method
Cmax
(μg/ml)
adjusted
R-squared
Estimated
T1/2 (days)
Lambda
(lower)*
Lambda
(upper)*
AUC
(INF_pred) Tlast*
Clast
(μg/ml)
AUC_%
Extrap_pred
2C5 Positive/Off 10
ELISA 201.1 0.997 6.60 7 28 592.6 28 2.6 4.1
TZM.bl 174.4 0.994 6.50 7 28 431.2 28 1.8 3.7
1E2 Negative 30
ELISA 360.8 0.930 14.48 7 56 4259.4 56 13.6 5.9
TZM.bl 1166.3 0.978 16.19 14 56 5901.2 56 16.1 6.2
1E3 Negative 30
ELISA 361.8 0.990 16.26 7 56 3177.5 56 11.7 8.2
TZM.bl 606.2 0.989 17.85 7 56 3422.2 56 12.3 9.3
1E5 Negative 30
ELISA 765.0 0.992 14.15 4 56 5874.2 56 16.3 5.7
TZM.bl 939.6 0.959 15.22 14 56 6424.5 56 19.1 6.1
2C1 Positive/Off 30
ELISA 410.2 0.991 5.80 7 28 1707.8 28 5.1 2.6
TZM.bl 717.4 0.993 5.99 7 42 2186.4 42 1.6 0.6
2D1 Positive/Off 30
ELISA 976.4 0.996 6.86 7 42 2494.9 42 3.4 1.3
TZM.bl 849.3 0.990 8.83 7 56 1825.5 56 1.1 0.8
2D3 Positive/Off 30
ELISA 571.0 0.962 13.39 7 56 3616.5 56 9.9 4.8
TZM.bl 953.7 0.993 11.23 7 42 4346.2 42 16.0 6.0
2E1 Positive/Off 30 ELISA 712.4 0.970 11.14 14 56 3028.5 56 4.6 2.3
2E2 Positive/Off 30 ELISA 789.4 0.920 11.14 7 56 3596.1 56 6.7 2.4
2E3 Positive/Off 30 ELISA 559.6 0.821 8.54 7 28 2495.6 28 13.7 8.4
Extended Data Table 5
Summary of 3BNC117 pharmakokinetics based on a 56-day period post infusion. (1) 
Estimation of half-lives; SD, standard deviation.
Dose HIV-1-status Subjects Method (subjects analyzed) Cmax (μg/ml) t1/2 (days) (1)
Mean SD Range Mean SD Range
1 mg Neg. 3
ELISA (3) 19.1 8.1 11.2 – 27.4 n.d. n.d. n.d.
TZM.bl (3) 26.2 2.4 23.5 – 27.8 n.d. n.d. n.d.
1 mg Pos. 3
ELISA (3) 24.1 9.1 15.7 – 33.8 n.d. n.d. n.d.
TZM.bl (1) 23.5 n.d. n.d. n.d. n.d. n.d.
3 mg Neg. 3
ELISA (3) 141.1 88.6 89.9 – 243.4 18.0 4.5 12.9 – 21.5
TZM.bl (3) 87.1 25.1 70.9 – 116.0 18.7 7.6 10.0 – 24.3
3 mg Pos. 3
ELISA (3) 73.7 35.7 32.6 – 97.6 9.2 0.4 8.7 – 9.6
TZM.bl (3) 50.6 15.7 32.6 – 61.7 11.2 2.2 9.5 – 13.73
10 mg Neg. 3
ELISA (3) 279.1 87.5 180.6 – 347.8 18.7 9.4 10.7 – 29.0
TZM.bl (3) 252.4 26.4 230.7 – 281.8 17.7 8.1 10.7 – 26.6
10 mg Pos. 3
ELISA (3) 235.4 80.0 178.2 – 326.8 8.1 2.4 6.6 – 10.9
TZM.bl (3) 213.6 52.6 174.4 – 273.4 8.8 4.3 6.5 – 13.7
30 mg Neg. 3
ELISA (3) 495.9 233.1 360.8 – 765.0 15.0 1.1 14.2 – 16.3
TZM.bl (3) 904.0 281.7 1166.3 – 606.2 16.4 1.3 15.2 –17.9
30 mg Pos. 6
ELISA (6) 669.8 199.7 410.2 – 976.4 9.9 3.3 5.8 – 13.7
TZM.bl (3) 840.1 118.4 717.4 – 953.7 8.9 2.3 6.7 – 11.2
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Dose HIV-1-status Subjects Method (subjects analyzed) Cmax (μg/ml) t1/2 (days) (1)
Mean SD Range Mean SD Range
All Neg. 12
ELISA (9) – – – 17.2 5.5 10.7 – 29.0
TZM.bl (9) – – – 17.6 5.7 10.0 – 26.6
All Pos. 15
ELISA (12) – – – 9.3 2.6 5.7 – 13.7
TZM.bl (9) – – – 9.6 2.9 6.1 – 13.7
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Pharmacokinetics of 3BNC117 in healthy and HIV-1-infected individuals
a. Diagrammatic representation of the study. Time of 3BNC117 infusion indicated by the 
red arrow, and sampling for 3BNC117 serum levels, HIV-1 viral load, CD4+/CD8+ counts 
and env sequencing indicated below. b. Antibody decay measured in TZM.bl assays (solid 
lines) and ELISA (dotted lines). Mean values and SEM for uninfected individuals (3 per 
group) are shown in blue and for HIV-1-infected individuals (2–5 per group) in red. Light 
gray indicates lower level of accuracy by the ELISA assay and dark gray by the TZM.bl 
assay. Open circles indicate levels lower than the accuracy threshold.
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Figure 2. HIV-1 viral load measurements
3BNC117 dose indicated in red. Plots (left-hand column) show absolute VLs in HIV-1 RNA 
copies/ml (y-axis) vs. time in days after infusion (x-axis; left panel). Log10 changes (right-
hand column) in VL from day 0. Red line illustrates the average (LS-mean, by mixed-effect 
linear model). Individual subjects are indicated on the right side. Subjects 2E1-5 were pre-
screened for 3BNC117-sensitivity. At 30 mg/kg dose level, the change in viremia was 
significant (p= 0.004, <0.001, <0.001, <0.001, 0.011 at days 4, 7, 14, 21, and 28, 
respectively) when compared to all available pretreatment values (Extended Data Table 2b).
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Figure 3. 3BNC117 sensitivity, changes in viremia, and 3BNC117 levels
3BNC117 dose is indicated on the top of the graphs. The left y-axis shows log10 change in 
viremia from baseline, and right y-axis shows antibody level measured in ELISA. Blue line 
reflects change in VL and dotted gray line antibody level. Numbers indicate IC50s for 
3BNC117 of autologous viral isolates measured by TZM.bl assay, color-coded as indicated 
on the top right.
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Figure 4. HIV-1 envelope sequence analysis after 3BNC117 infusion
a. HIV-1 envelopes were cloned from plasma samples. Logogram showing Env gp120 
regions (amino acid positions; 270–285, 360–371, and 455 to 471–485, according to HXBc2 
numbering) indicating sequence changes from day 0 (blue bar) to day 28 (red bar). The 
frequency of each amino acid is indicated by its height. Red residues represent mutations 
that were only found after treatment, black residues represent amino acids that changed in 
frequency after treatment, empty boxes represent gaps, and + symbols represent 3BNC117 
contact sites on gp12030. b. Phylogenetic trees show gp120 evolution from day 0 to 28 after 
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treatment for 2C1, 2C5, 2D1, 2E1 and 2E2. Blue and red bars represent sequences obtained 
on days 0 and 28 (Supplementary Fig. 1). Illustrated values represent the IC50 of 3BNC117 
in μg/ml against the cloned HIV-1 pseudoviruses from the analyzed sequences (Extended 
Data Table 3). The geometric means of the pseudoviruses’ IC50s on days 0 and 28 
respectively are for 2C1: 0.06 and 0.14 μg/ml; 2C5: 0.02 and 7.09 μg/ml; 2D1: 0.15 and 
0.52; 2E1: 0.09 and 0.23 μg/ml; 2E2: 0.01 and 0.03 μg/ml.
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Table 1
Study participants demographics
Uninfected (n = 12) HIV-1-infected (n = 17)
Gender (% male) 83% 76%
Mean Age (range) 43 (22 – 58) 37 (20 – 54)
Race/Ethnicity
White 42% 29%
Black or African American 50% 53%
Hispanic 8% 18%
ART status
On ART n (%) – 2 (12%)
Off ART n (%) – 15 (88%)
Mean abs. CD4+ count
(cells/μl; day 0) – 655 (245 – 1,129)
Mean % CD4+ count (day 0) – 29% (20 – 42%)
Mean HIV-1 RNA level
(copies/ml; day 0)* – 9,420 (640 – 53,470)
*
Mean HIV-1 RNA levels in HIV-1-infected participants off ART
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